Threshold Pharmaceuticals' Partner Merck KGaA, Darmstadt, Germany Initiates Phase 1 Dose Escalation Study of TH-302 in Combination With Gemcitabine and Nab-paclitaxel (Abraxane(R)) in Pancreatic Cancer